No Data
Frontier Biotech (688221.SH): FB3002 Loxoprofen Sodium Patch has received the notification of acceptance for domestic pharmaceutical production registration and marketing license.
On January 20, Gelonghui reported that Frontier Bio (688221.SH) announced that its product under research, FB3002 (a hot melt adhesive patch for the treatment of musculoskeletal joint pain), has received a "Notice of Acceptance" for its generic drug marketing application issued by the National Medical Products Administration. FB3002, a high-end generic drug for the treatment of musculoskeletal joint pain, contains the active ingredient Loxoprofen Sodium, which is a non-steroidal anti-inflammatory pain reliever. Its mechanism of action is to inhibit the activity of cyclooxygenase, thereby suppressing the synthesis of prostaglandins, resulting in good analgesic and anti-inflammatory effects, especially in terms of pain relief.
Frontier Biotech 2024 Annual Performance Forecast
Qianyan Biology (688221.SH): Expected loss of 0.182 billion yuan to 0.22 billion yuan in 2024.
Gelonghui reported on January 17 that Frontier Bio (688221.SH) announced the annual performance forecast for 2024. According to preliminary estimates by the financial department, it is expected that the revenue for 2024 will be approximately 125 million to 130 million yuan, an increase of 9.41% to 13.79% year-on-year, mainly due to revenue growth from the anti-HIV Innovative Drugs product Aikenin and diversified business. According to preliminary estimates by the financial department, it is expected that the Net income attributable to shareholders of the listed company will show a loss of approximately 182 million to 220 million yuan, with a reduction in losses of about 10.
Is Frontier Biotechnologies (SHSE:688221) Weighed On By Its Debt Load?
Frontier Biotech (688221.SH) subsidiary sichuan frontier passes the pharmaceutical GMP compliance inspection.
Frontier Biotechnology (688221.SH) announced that the company has received the approval and issuance of supplementary pharmaceuticals by the National Medical Products Administration...
Frontier Biotech (688221.SH): Aikening's new maintenance treatment indication obtained the Phase II clinical trial approval notice.
Frontbio (688221.SH) announced on November 5th that the company has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, allowing the company to conduct a Phase II clinical trial for expanding the indications of its marketed product EKoning for maintenance therapy according to the submitted plan. EKoning is a domestically developed Class 1.1 new drug, the world's first long-acting HIV fusion inhibitor approved in the major global markets with independent intellectual property rights. EKoning, when used in combination with other antiretroviral drugs, is effective against the prevalent HIV-1 virus and resistant viruses, with a reduced dosing frequency.